510(k) Report

510(k) · Cleared

Cleared

Osmosys Calcium Phosphate Ceramic Bone Filler

K050490510(k) TraditionalCleared Apr 11, 200545-day reviewClass II21 CFR 888.3045

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Medicrea · MQV Filler, Bone Void, Calcium Compound

Cleared on Apr 11, 2005 as substantially equivalent to K030178 (Biomet, Inc., 2003) and 1 other predicate after a 45-day review. Its family tree reaches back 4 generations to 1996.

Decided
Apr 11, 2005
Review
45 days
Class
Class II
Product code
MQV
Recalls
None
Predicates
2

Its longest line of descent runs back 4 generations to K960978 (1996). 14 ancestors in all. No later device cites it as a predicate yet.

  1. Root · 4 generations backK960978 Wright Plaster of Paris Pellets (Subject to Revision)Wrightmedicaltechnologyinc · 1996
  2. 3 generations backK980817 Pro Osteon Implant 500R Resorbable Bone Graft Substitute Model…Interpore Intl. · 1998
  3. 2 generations backK013960 Apatight HA-Bone Graft SubstituteCerabio, LLC · 2002
  4. 1 generation backK030178 Calcigen Psi Bone Graft SubstituteBiomet, Inc. · 2003
  5. This deviceK050490 Osmosys Calcium Phosphate Ceramic Bone FillerMedicrea · 2005
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−4K960978Wright Plaster of Paris Pellets (Subject to Revision)Wrightmedicaltechnologyinc1996—
−3K980817Pro Osteon Implant 500R Resorbable Bone Graft Substitute Model Numbers 5RG05…Interpore Intl.1998—
−2K013960Apatight HA-Bone Graft SubstituteCerabio, LLC2002—
−1K030178Calcigen Psi Bone Graft SubstituteBiomet, Inc.2003—
0 (this device)K050490Osmosys Calcium Phosphate Ceramic Bone FillerMedicrea2005—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
199710
199910
200010
200110
200260
FIG. 1 — Lineage of K050490, 1996–2005Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in MQV? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new MQV device

  1. #1 K232315 Catalyst Bone Void Fillerscore 25.2 · 25 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (2)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K030178Calcigen Psi Bone Graft Substitute
Summary page 1
…Filler, calciumr sulfite, preformed pellets Class II per 21 CFR section 888.3045 Product Code MQV Equivalent I)evice Calcigen (K030178) (Biomet - Warsaw, IN) Maslergrafi Resorbable Ceramic (K020986) (Medtronic Sofamor Danek -…
Biomet, Inc.2003—
*K020986Mastergraft Resorbable Ceramic
Summary page 1
…R section 888.3045 Product Code MQV Equivalent I)evice Calcigen (K030178) (Biomet - Warsaw, IN) Maslergrafi Resorbable Ceramic (K020986) (Medtronic Sofamor Danek - Memphis.TN ). I)evice l)escription OSMOSYS is a synthetic bone substitute co…
Medtronic Sofamor Danek, Inc.2002—

Also cleared against K030178: 1 other device →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 9 years and passes through 5 companies; a new generation was cleared every 2.3 years on median.
  • None of the 14 ancestors has a recall.
  • 1 other device also cites its predicate K030178.

How does its category compare?

All MQV devices

MQV Filler, Bone Void, Calcium Compound: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · MQV

14in 2025

2007: 352008: 322009: 232010: 172011: 162012: 92013: 122014: 202015: 182016: 82017: 172018: 232019: 132020: 152021: 82022: 92023: 212024: 282025: 142026 (partial year): 5
2007high 35 (2007) · low 8 (2016)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · MQV

57in 2025

2007: 144 days median2008: 102 days median2009: 180 days median2010: 147 days median2011: 92 days median2012: 107 days median2013: 197 days median2014: 153 days median2015: 184 days median2016: 214 days median2017: 124 days median2018: 124 days median2019: 90 days median2020: 132 days median2021: 88 days median2022: 118 days median2023: 74 days median2024: 55 days median2025: 57 days median2026 (partial year): 96 days median
2007high 214 (2016) · low 55 (2024)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · MQV

1in 2025

2007: 52008: 32009: 12011: 62012: 32013: 22016: 12017: 12018: 22020: 12023: 32024: 22025: 12026 (partial year): 4
2007high 6 (2011) · low 0 (2010)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · MQV

57in 2025

2007: 672008: 712009: 812010: 682011: 1142012: 1492013: 2232014: 1112015: 1252016: 1062017: 1072018: 862019: 652020: 1262021: 1012022: 472023: 1202024: 682025: 57
2007high 223 (2013) · low 47 (2022)2025

MAUDE reports naming product code MQV, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
200735144567
200832102371
200923180181
201017147068
201116926114
201291073149
2013121972223
2014201530111
2015181840125
201682141106
2017171241107
201823124286
20191390065
2020151321126
20218880101
20229118047
202321743120
20242855268
20251457157
20265964—

What is it indicated for?

OSMOSYS is intended for use as a bone void filler to fill bony void gaps of the skeletal system (i.e. the extremities, spine and pelvis) resulting from surgery or trauma that are not intrinsic to the stability of the bony structure. OSMOSYS is indicated for use in the treatment of surgically created osseous defects or osseous defects created from traumatic injury to bone. Following placement in the bony voids or gap, OSMOSYS resorbs and is replaced with bone during the healing process.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K050490: Osmosys Calcium Phosphate Ceramic Bone Filler.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 3, 2026. https://510kreport.com/device/K050490

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026